Protalix BioTherapeutics (PLX) Receivables (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Receivables of $2.9 million for Q1 2026, down 37.13% year-over-year from $4.7 million in Q1 2025, and down 66.75% quarter-over-quarter from $8.8 million in Q4 2025.
Protalix BioTherapeutics (PLX) Receivables (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Receivables history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Receivables fell 37.13% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 37.13% YoY), while the FY2025 annual figure was $8.8 million, up 203.88% from the prior year.
- Receivables for Q1 2026 stood at $2.9 million, down from $8.8 million in the prior quarter.
- The five-year high for Receivables was $14.4 million in Q3 2025, with the low at $1.3 million in Q1 2023.
- The 5-year median for Receivables is $4.7 million (2025), against an average of $5.9 million.
- The sharpest annual moves came in 2023 and 2025: Receivables sank 77.93% in 2023, then jumped 557.18% in 2025.
- Protalix BioTherapeutics' Receivables stood at $4.6 million in 2022, then grew by 14.96% to $5.3 million in 2023, then sank by 44.82% to $2.9 million in 2024, then jumped by 203.88% to $8.8 million in 2025, then tumbled by 66.75% to $2.9 million in 2026.
- Business Quant data shows PLX's Receivables at $2.9 million in Q1 2026, $8.8 million in Q4 2025, and $14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 16.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.50 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 14.43 Mn |
| Jun 30, 2025 | 9.44 Mn |
| Mar 31, 2025 | 4.68 Mn |
| Dec 31, 2024 | 2.91 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 10.13 Mn |
| Mar 31, 2024 | 3.76 Mn |
| Dec 31, 2023 | 5.27 Mn |
| Sep 30, 2023 | 8.94 Mn |
| Jun 30, 2023 | 4.05 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | 4.59 Mn |
| Sep 30, 2022 | 8.65 Mn |
| Jun 30, 2022 | 2.02 Mn |
| Mar 31, 2022 | 5.91 Mn |
| Dec 31, 2021 | 3.44 Mn |
| Sep 30, 2021 | 5.56 Mn |